As PBL is an aggressive non-Hodgkin lymphoma, a delayed diagnosis might negatively impact on both treatment and survival.doi:10.1097/MD.0000000000022335Zizzo, MaurizioZanelli, MagdaMartiniani, RobertaSanguedolce, FrancescaDe Marco, LoredanaMartino, Giovanni...
Prognosis: this is an aggressive lymphoma with a median survival of just 8 months.20 Pitfall: plasmablastic lymphoma has an immunophenotypic profile virtually identical to plasmablastic plasma cell myeloma. However, EBV positivity is seen in plasmablastic lymphoma and not generally in plasmablastic pl...
Citation20 In fact, loss of Blimp1 protein expression has recently been found to be associated with MYC overexpression, and decreased expression of p53 tumor-suppressor molecules in ABC-like diffuse large B-cell lymphoma (DLBCL).Citation21 Clinical features, survival, and prognostic factors PbL is...
Plasmablastic lymphoma (PBL) is an aggressive neoplasm exclusively occurring in AIDS patients. Recently, increasing cases of human immunodeficiency virus (HIV)-negative PBL have been reported. No standard therapy protocol is currently available since the
People above the age of 50 years are more commonly affected, with male predominance having a survival rate of 8 to 15 months. Here, we describe the case of a 48-year-old man who had an isolated plasmablastic lymphoma of the right sphenoid bone without any immunodeficiency. Plasmablastic ...
Plasmablastic Lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma with a low survival rate. It is associated with Human Immunodeficiency Virus (HIV) infection but also affects patients with autoimmune diseases as chronic lymphocytic leukaemia...
Despite advances in our comprehension of this disease, the prognosis remains dismal, resulting in a low overall survival rate, although recent reports suggest an apparent tendency towards substantial improvement.Bibas, MicheleMediterranean Journal of Hematology & Infectious Diseases...
In spite of the fact that we have improved our knowledge of this disease, the prognosis is still unfavorable, and the overall survival rate is low. There is no defined standard of care appropriate for this lymphoma. There have been a number of different chemotherapy combinations used, with ...
Introduction: Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of large B-cell lymphoma with plasmacytic differentiation. Although limited-stage (LS) PBL has a favorable outcome, extensive-stage (ES) PBL has a poor prognosis, with a median survival of 12-18 months. Patients with...
Overall survival (OS) of patients with acquired immunodeficiency syndrome (AIDS)-related Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL) was analysed in the German AIDS-related-Lymphoma-Cohort-Study. Of 291 patients prospectively included between January...